Breast Cancer

Leah Katz, MD, MPH, discusses IDEA, TARGIT-B, NeoORB, and other breast radiation data from ASTRO 2026, and why patient selection is the unifying theme.

Nikolai Strusberg, MD, discussed how proton therapy and thyroid dose affect clinical hypothyroidism risk after supraclavicular breast radiation.

Data from the phase 3 HER2CLIMB-05 study support the FDA approval of tucatinib-based maintenance treatment in HER2-positive metastatic breast cancer.

In the phase 3 evERA trial, interim overall survival data showed a positive trend in favor of giredestrant/everolimus vs endocrine therapy plus everolimus.

10-year CHN HYPOPMRT data show 3-week postmastectomy RT with nodal irradiation maintains locoregional control without added severe late toxicity.

T-DXd and Dato-DXd are now approved treatments in Japan for patients with breast cancer.

Data from the phase 3 EMBER-3 trial support the full approval of imlunestrant plus abemaciclib in this breast cancer population.

NICE recommended trastuzumab deruxtecan for reimbursement in England for HER2-low metastatic breast cancer, backed by DESTINY-Breast04 data.

Trastuzumab botidotin more than doubled median PFS vs trastuzumab emtansine in HER2-positive advanced breast cancer in the phase 3 KL166-III-06 trial.

Camizestrant/palbociclib did not significantly improve PFS vs anastrozole/palbociclib in first-line ER+/HER2– breast cancer in the phase 3 SERENA-4 trial.

Adding atezolizumab to neoadjuvant chemotherapy did not significantly improve EFS in early TNBC, but node-positive and high-TIL subgroups showed benefit.

Lisa Cassileth, MD, FACS, discussed how BMI and mastectomy flap quality drive MSFN risk more than implant-specimen size difference.

Lisa Cassileth, MD, FACS, explained her initial interpretation of lower mastectomy flap necrosis rates in an upsized implant group.

Lisa Cassileth, MD, FACS, discussed why she investigated whether upsizing breast implants increased mastectomy flap necrosis risk.

FDA approved camizestrant for HR+/HER2– advanced breast cancer with emerging ESR1 mutations based on data from the SERENA-6 trial.

Experts in breast cancer discussed final CAPItello-291 overall survival data and their implications for capivasertib plus fulvestrant.

Lisa Cassileth, MD, FACS, discussed her retrospective study showing that upsizing breast implants does not increase mastectomy flap necrosis risk.

Neil Iyengar, MD; Rebecca Shatsky, MD; and Carol Tweed, MD, discuss camizestrant and SERENA-6 ctDNA monitoring for ESR1-mutant HR+/HER2– breast cancer.

The European Commission has approved T-DXd plus pertuzumab as first-line therapy for HER2-positive metastatic breast cancer based on DESTINY-Breast09.

ASCO’s updated breast cancer follow-up guideline replaces routine, one-size-fits-all surveillance with a 3-tier, risk-based model.

Paxalisib produced a 100% clinical benefit rate and an 83% objective response rate in patients with metastatic triple-negative breast cancer.

The regulatory submission to expand the gedatolisib label to HR+/HER2-, PIK3CA-mutant advanced breast cancer is based on positive VIKTORIA-1 trial data.

Ami Shah, MD, Megan Kruse, MD, and Ruta Rao, MD, discuss DESTINY-Breast09, -11, and -05 data on trastuzumab deruxtecan in HER2-positive breast cancer.

Patrick Borgen, MD built Brooklyn's breast cancer program from 47 patients to 8000. Now he and Joshua Feinberg, MD discuss what surgery looks like next.

A multidisciplinary panel broke down ILC's distinct biology, imaging challenges, and emerging trial data, including OFSET and SUMMIT.